SCLX (Scilex Holding Co) 3-Month Share Buyback Ratio: 0.00% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCLX Scilex Holding Co SCLX
56 GF Score
Price $6.80
GF Value $5.83
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co 3-Month Share Buyback Ratio?

Scilex Holding Co SCLX -2.00% 56 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates SCLX with a GF Score™ of 56/100 and a GF Value™ of $5.83 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Scilex Holding Co's current 3-Month Share Buyback Ratio was 0.00%.


Scilex Holding Co  (NAS:SCLX) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Scilex Holding Co 3-Month Share Buyback Ratio Related Terms


SCLX vs MIRA, NSRX, MDCX: 3-Month Share Buyback Ratio Comparison

For the Drug Manufacturers - General subindustry, Scilex Holding Co's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scilex Holding Co 3-Month Share Buyback Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's 3-Month Share Buyback Ratio falls into.


SCLX
56GF Score
Scilex Holding Co SCLX
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scilex Holding Co 3-Month Share Buyback Ratio Calculation

Scilex Holding Co's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(7.033 - 7.033) / 7.033
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
Scilex Holding Co (SCLX) has a 3-Month Share Buyback Ratio of 0.00 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Scilex Holding Co and its competitors.
Is Scilex Holding Co's 3-Month Share Buyback Ratio too high?
Scilex Holding Co's current 3-Month Share Buyback Ratio is 0.00. Overall, Scilex Holding Co has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's 3-Month Share Buyback Ratio compare to MIRA and NSRX?
Scilex Holding Co's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Month Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Scilex Holding Co and its competitors. Scilex Holding Co's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.83, compared to a current price of $6.80 — trading 16.6% above its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Scilex Holding Co's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scilex Holding Co (SCLX) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued. The current stock price of $6.80 is trading 16.6% above its estimated GF Value™ of $5.83. GuruFocus considers Scilex Holding Co to be Modestly Overvalued.

Key valuation signals for SCLX:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $5.83 vs. price of $6.80 (16.6% above fair value)
  • GF Score™: 56/100 with 7 warning signs

No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scilex Holding Co Business Description

Other Exchanges D8B0:Germany
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
56GF Score

Get the complete analysis for SCLX

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.80
Price
$5.83
GF Value